tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2021 Dec 23;9(2)
fab632.
doi: 10.1093/ofid/ofab632. eCollection 2022 Feb.
Adapting Serosurveys for the SARS-CoV-2 Vaccine Era
Nathan Duarte[SUP] 1 [/SUP], Mercedes Yanes-Lane[SUP] 2 [/SUP], Rahul K Arora[SUP] 3 4 [/SUP], Niklas Bobrovitz[SUP] 5 6 [/SUP], Michael Liu[SUP] 7 [/SUP], Mariana G Bego[SUP] 2 [/SUP], Tingting Yan[SUP] 5 [/SUP], Christian Cao[SUP] 3 [/SUP], Celine Gurry[SUP] 8 [/SUP], Catherine A Hankins[SUP] 2 9 [/SUP], Matthew Pellan Cheng[SUP] 10 [/SUP], Anne-Claude Gingras[SUP] 11 12 [/SUP], Bruce D Mazer[SUP] 2 13 [/SUP], Jesse Papenburg[SUP] 9 14 15 [/SUP], Marc-André Langlois[SUP] 16 17 [/SUP]
Affiliations
Abstract
Population-level immune surveillance, which includes monitoring exposure and assessing vaccine-induced immunity, is a crucial component of public health decision-making during a pandemic. Serosurveys estimating the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the population played a key role in characterizing SARS-CoV-2 epidemiology during the early phases of the pandemic. Existing serosurveys provide infrastructure to continue immune surveillance but must be adapted to remain relevant in the SARS-CoV-2 vaccine era. Here, we delineate how SARS-CoV-2 serosurveys should be designed to distinguish infection- and vaccine-induced humoral immune responses to efficiently monitor the evolution of the pandemic. We discuss how serosurvey results can inform vaccine distribution to improve allocation efficiency in countries with scarce vaccine supplies and help assess the need for booster doses in countries with substantial vaccine coverage.
Keywords: 19; 2; COVID; CoV; SARS; cross; sectional; seroprevalence; vaccines.
. 2021 Dec 23;9(2)
fab632.doi: 10.1093/ofid/ofab632. eCollection 2022 Feb.
Adapting Serosurveys for the SARS-CoV-2 Vaccine Era
Nathan Duarte[SUP] 1 [/SUP], Mercedes Yanes-Lane[SUP] 2 [/SUP], Rahul K Arora[SUP] 3 4 [/SUP], Niklas Bobrovitz[SUP] 5 6 [/SUP], Michael Liu[SUP] 7 [/SUP], Mariana G Bego[SUP] 2 [/SUP], Tingting Yan[SUP] 5 [/SUP], Christian Cao[SUP] 3 [/SUP], Celine Gurry[SUP] 8 [/SUP], Catherine A Hankins[SUP] 2 9 [/SUP], Matthew Pellan Cheng[SUP] 10 [/SUP], Anne-Claude Gingras[SUP] 11 12 [/SUP], Bruce D Mazer[SUP] 2 13 [/SUP], Jesse Papenburg[SUP] 9 14 15 [/SUP], Marc-André Langlois[SUP] 16 17 [/SUP]
Affiliations
- PMID: 35103246
- PMCID: PMC8755308
- DOI: 10.1093/ofid/ofab632
Abstract
Population-level immune surveillance, which includes monitoring exposure and assessing vaccine-induced immunity, is a crucial component of public health decision-making during a pandemic. Serosurveys estimating the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the population played a key role in characterizing SARS-CoV-2 epidemiology during the early phases of the pandemic. Existing serosurveys provide infrastructure to continue immune surveillance but must be adapted to remain relevant in the SARS-CoV-2 vaccine era. Here, we delineate how SARS-CoV-2 serosurveys should be designed to distinguish infection- and vaccine-induced humoral immune responses to efficiently monitor the evolution of the pandemic. We discuss how serosurvey results can inform vaccine distribution to improve allocation efficiency in countries with scarce vaccine supplies and help assess the need for booster doses in countries with substantial vaccine coverage.
Keywords: 19; 2; COVID; CoV; SARS; cross; sectional; seroprevalence; vaccines.